Gregory J. Tsongalis, BS, MS, PhD
Professor of Pathology and Laboratory Medicine
Director, Clinical Genomics and Advanced Technology (CGAT)
Pathology and Laboratory Medicine
Univ. of Massachusetts, Amherst, BS, 1984
Quinnipiac College, MHS, 1986
Univ. of Medicine and Dentistry of New Jersey, PhD 1990
Uniiv. of North Carolina, Chapel Hill, post-doctoral 1990-1994
Norris Cotton Cancer Center
Program in Experimental and Molecular Medicine
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon NH 03756
Development of advanced diagnostic technologies and disease biomarker discovery.
01/2014-12/30/15; Molecular profiling of tumor and ctDNA, riends of NCCC Scholar $50,000
03/01/13-01/31/2018; 1P20GM104416, Investigator / 2% COBRE Center for Molecular Epidemiology, Federal Direct Costs: $1,793,732
A case of molecularly confirmed BAP1 Inactivated Melanocytic Tumor with retention of immunohistochemical expression: A confounding factor.
MicroRNAs in graft-versus-host disease: a review of the latest data.
BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease.
Third-Generation Sequencing in the Clinical Laboratory: Exploring the Advantages and Challenges of Nanopore Sequencing.
How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market.
Screening for Human Papillomavirus in a Low- and Middle-Income Country.
Pancreatic cyst fluid harboring a KRAS mutation.
Design of peptide nucleic acid probes on plasmonic gold nanorods for detection of circulating tumor DNA point mutations.
Significant Expansion of Real-Time PCR Multiplexing with Traditional Chemistries using Amplitude Modulation.
Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.